{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:00:29Z","timestamp":1790175629495,"version":"4.1.0"},"reference-count":138,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>\n                    Rare and ultra-rare solid tumors collectively account for approximately one-quarter of all cancer diagnoses yet remain associated with poor clinical outcomes. Delayed diagnosis, limited biological characterization, few therapeutic options, and the logistical challenges of conducting adequately powered clinical trials underscore the potential for adaptable cellular immunotherapies that can be applied across diverse tumor histologies. Natural killer (NK) cells have emerged as a promising platform for adoptive cell therapy because of their ability to recognize and eliminate malignant cells independently of major histocompatibility complex restriction, their favorable safety profile, and their suitability for standardized allogeneic, off-the-shelf manufacturing. This review examines the progression of NK cell-based therapies from their biological and therapeutic foundations in solid tumors to their emerging application in rare and ultra-rare malignancies. Recent advances in NK cell engineering are enabling multifunctional cell products designed to enhance tumor recognition, trafficking, persistence, and resistance to the immunosuppressive tumor microenvironment. We also review emerging clinical evidence demonstrating the feasibility and safety of these approaches while highlighting the major biological and translational barriers that continue to limit durable responses. Building on these advances, attention is given to the unique challenges of rare and ultra-rare cancers, where small patient populations, tumor heterogeneity, limited therapeutic targets, and logistical constraints pose unique challenges to conventional drug and cellular therapy development. Finally, we discuss how scalable off-the-shelf manufacturing, rational combination strategies, innovative clinical trial designs, and next-generation technologies, including multiplex gene editing, armored NK cells, and\n                    <jats:italic>in vivo<\/jats:italic>\n                    engineering, may facilitate this translation. Collectively, progress in NK cell therapy across solid tumors provides a framework for extending increasingly adaptable and scalable immunotherapeutic platforms to rare and ultra-rare malignancies, with the potential to expand treatment opportunities for patient populations that have historically had limited therapeutic options.\n                  <\/jats:p>","DOI":"10.3389\/fmolb.2026.1955532","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:04:52Z","timestamp":1790172292000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic reprogramming of natural killer cells for solid tumors: expanding frontiers into rare and ultra-rare malignancies"],"prefix":"10.3389","volume":"13","author":[{"given":"Francesca","family":"Rosato","sequence":"first","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Hodge","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"0023","DOI":"10.34133\/cancomm.0023","article-title":"Harnessing the power of CAR-NK cells for solid tumors: challenges, innovations, and future frontiers in immunotherapy","volume":"46","author":"An","year":"2026","journal-title":"Cancer Commun. (Lond)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andre","year":"2018","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/14653240802301872","article-title":"Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial","volume":"10","author":"Arai","year":"2008","journal-title":"Cytotherapy"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1574742","DOI":"10.3389\/fimmu.2025.1574742","article-title":"CAR-NK cell therapy: promise and challenges in solid tumors","volume":"16","author":"Balkhi","year":"2025","journal-title":"Front. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-beta signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"key":"B7","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","volume":"141","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"100861","DOI":"10.1016\/j.lanepe.2024.100861","article-title":"Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN","volume":"39","author":"Blay","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5632","DOI":"10.1002\/cam4.3137","article-title":"Incidence and survival of rare cancers in the US and Europe","volume":"9","author":"Botta","year":"2020","journal-title":"Cancer Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S1470-2045(15)00386-1","article-title":"Rare cancers: a sea of opportunity","volume":"17","author":"Boyd","year":"2016","journal-title":"Lancet Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1517\/21678707.2016.1120663","article-title":"Developing therapies for rare tumors: opportunities, challenges and progress","volume":"4","author":"Bradford","year":"2016","journal-title":"Expert Opin. Orphan Drugs"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1182\/blood-2008-05-156836","article-title":"The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells","volume":"113","author":"Brodin","year":"2009","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s43441-024-00670-1","article-title":"A systematic review of adaptive seamless clinical trials for late-phase oncology development","volume":"58","author":"Broglio","year":"2024","journal-title":"Ther. Innov. Regul. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1084\/jem.20051143","article-title":"Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells","volume":"202","author":"Bryceson","year":"2005","journal-title":"J. Exp. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e000666","DOI":"10.1136\/esmoopen-2019-000666","article-title":"Rationale of the rare cancer list: a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU)","volume":"5","author":"Casali","year":"2020","journal-title":"ESMO Open"},{"key":"B18","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1093\/annonc\/mdu459","article-title":"Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper","volume":"26","author":"Casali","year":"2015","journal-title":"Ann. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/cmi.2013.10","article-title":"NK cell-based immunotherapy for malignant diseases","volume":"10","author":"Cheng","year":"2013","journal-title":"Cell Mol. Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1038\/s41590-023-01659-y","article-title":"Forks in the road for CAR T and CAR NK cell cancer therapies","volume":"24","author":"Dagher","year":"2023","journal-title":"Nat. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"R125","DOI":"10.1186\/ar2336","article-title":"The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors","volume":"9","author":"de Rham","year":"2007","journal-title":"Arthritis Res. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10555-025-10273-3","article-title":"Prospects and limitations of NK cell adoptive therapy in clinical applications","volume":"44","author":"Deng","year":"2025","journal-title":"Cancer Metastasis Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3322\/caac.21400","article-title":"The burden of rare cancers in the United States","volume":"67","author":"DeSantis","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"B24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4049\/immunohorizons.2300099","article-title":"Chimeric antigen cytotoxic receptors for in vivo engineering of tumor-targeting NK cells","volume":"8","author":"Diwanji","year":"2024","journal-title":"Immunohorizons"},{"key":"B25","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3390\/cancers13020312","article-title":"Engineering anti-tumor monoclonal antibodies and Fc receptors to enhance ADCC by human NK cells","volume":"13","author":"Dixon","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12935-026-04219-0","article-title":"Beyond CRISPR: next-gen precision engineering of CAR-NK cells for enhanced persistence, trafficking, and tumor eradication","volume":"26","author":"Dong","year":"2026","journal-title":"Cancer Cell Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1158\/1078-0432.CCR-24-1991","article-title":"First-in-Human phase I study of a CD16A bispecific innate cell engager, AFM24, targeting EGFR-expressing solid tumors","volume":"31","author":"El-Khoueiry","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"834002","DOI":"10.3389\/fonc.2022.834002","article-title":"CRISPR gene editing of human primary NK and T cells for cancer immunotherapy","volume":"12","author":"Elmas","year":"2022","journal-title":"Front. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.omto.2021.10.001","article-title":"The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy","volume":"23","author":"Fabian","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e000450","DOI":"10.1136\/jitc-2019-000450","article-title":"PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations","volume":"8","author":"Fabian","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1182\/blood-2009-08-238469","article-title":"Regulation of human NK-cell cytokine and chemokine production by target cell recognition","volume":"115","author":"Fauriat","year":"2010","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/978-1-4939-3684-7_28","article-title":"Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells","volume":"1441","author":"Felices","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.3390\/vaccines10121993","article-title":"Disruption of the NKG2A:HLA-E immune checkpoint axis to enhance NK cell activation against cancer","volume":"10","author":"Fisher","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1053\/j.seminoncol.2015.05.015","article-title":"Anticancer cytokines: biology and clinical effects of Interferon-alpha2, interleukin (IL)-2, IL-15, IL-21, and IL-12","volume":"42","author":"Floros","year":"2015","journal-title":"Semin. Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1158\/1078-0432.CCR-14-2675","article-title":"The evolution of T-cell therapies for solid malignancies","volume":"21","author":"Fousek","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1158\/2326-6074.IO2026-A018","volume-title":"Characterization of the Anti-tumor Efficacy of Memory Cytokine Enriched NK Cells Against Tumors with Neuroendocrine Features","author":"Fousek","year":"2026"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.3390\/cancers12082131","article-title":"Natural born killers: NK cells in cancer therapy","volume":"12","author":"Franks","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B38","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.immuni.2017.10.008","article-title":"The broad spectrum of human natural killer cell diversity","volume":"47","author":"Freud","year":"2017","journal-title":"Immunity"},{"key":"B39","doi-asserted-by":"publisher","first-page":"33498","DOI":"10.18632\/oncotarget.9256","article-title":"Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab","volume":"7","author":"Fujii","year":"2016","journal-title":"Oncotarget"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3171\/2017.1.JNS162610","article-title":"A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab","volume":"128","author":"Fujii","year":"2018","journal-title":"J. Neurosurg."},{"key":"B41","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1186\/s13287-025-04461-9","article-title":"Human iPSC-derived NK cells armed with CCL19, CCR2B, high-affinity CD16, IL-15, and NKG2D complex enhance anti-solid tumor activity","volume":"16","author":"Fukutani","year":"2025","journal-title":"Stem Cell Res. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ejca.2021.09.003","article-title":"A phase II study of monalizumab in patients with recurrent\/metastatic squamous cell carcinoma of the head and neck: the I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial","volume":"158","author":"Galot","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1791059","DOI":"10.3389\/fimmu.2026.1791059","article-title":"Advances in IL-15-Based cancer immunotherapy and divergent immunological effects of IL-2 and IL-15 signaling via the shared IL-2Rbetagamma receptor","volume":"17","author":"Gao","year":"2026","journal-title":"Front. Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1016\/j.ejca.2011.08.008","article-title":"Rare cancers are not so rare: the rare cancer burden in Europe","volume":"47","author":"Gatta","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e01973","DOI":"10.1002\/smtd.202501973","article-title":"Nano-therapeutics for in vivo immune cell engineering","volume":"10","author":"Geng","year":"2026","journal-title":"Small Methods"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e130688","DOI":"10.1172\/jci.insight.130688","article-title":"Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK","volume":"4","author":"Giles","year":"2019","journal-title":"JCI Insight"},{"key":"B47","doi-asserted-by":"publisher","first-page":"841107","DOI":"10.3389\/fimmu.2022.841107","article-title":"iPSC-Derived natural killer cell therapies - expansion and targeting","volume":"13","author":"Goldenson","year":"2022","journal-title":"Front. Immunol."},{"key":"B48","first-page":"652","article-title":"Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells","volume":"8","author":"Gong","year":"1994","journal-title":"Leukemia"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1298683","DOI":"10.3389\/fimmu.2023.1298683","article-title":"Synergistic treatment strategy: combining CAR-NK cell therapy and radiotherapy to combat solid tumors","volume":"14","author":"He","year":"2023","journal-title":"Front. Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.conctc.2018.08.009","article-title":"Master protocol trials in oncology: review and new trial designs","volume":"12","author":"Hirakawa","year":"2018","journal-title":"Contemp. Clin. Trials Commun."},{"key":"B51","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1172\/JCI129338","article-title":"Killers 2.0: NK cell therapies at the forefront of cancer control","volume":"129","author":"Hodgins","year":"2019","journal-title":"J. Clin. Invest"},{"key":"B52","doi-asserted-by":"publisher","first-page":"586168","DOI":"10.3389\/fimmu.2020.586168","article-title":"HLA class I knockout converts allogeneic primary NK cells into suitable effectors for \u201cOff-the-Shelf\u201d immunotherapy","volume":"11","author":"Hoerster","year":"2020","journal-title":"Front. Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"101943","DOI":"10.1016\/j.tranon.2024.101943","article-title":"Targeting sinonasal undifferentiated carcinoma with a combinatory immunotherapy approach","volume":"44","author":"Hoke","year":"2024","journal-title":"Transl. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"PO.19.00086","DOI":"10.1200\/PO.19.00086","article-title":"Biomarker-driven oncology clinical trials: key design elements, types, features, and practical considerations","volume":"3","author":"Hu","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.3389\/fimmu.2019.01205","article-title":"Cancer immunotherapy based on natural killer cells: current progress and new opportunities","volume":"10","author":"Hu","year":"2019","journal-title":"Front. Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2256904","DOI":"10.1080\/21645515.2023.2256904","article-title":"Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer","volume":"19","author":"Huan","year":"2023","journal-title":"Hum. Vaccin Immunother."},{"key":"B57","volume-title":"FDA Authorizes Immunitybio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid Tumors","year":"2021"},{"key":"B58","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1158\/1078-0432.CCR-23-0156","article-title":"Memory-like differentiation, tumor-targeting mAbs, and chimeric antigen receptors enhance natural killer cell responses to head and neck cancer","volume":"29","author":"Jacobs","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B59","doi-asserted-by":"publisher","first-page":"86359","DOI":"10.18632\/oncotarget.13411","article-title":"An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele","volume":"7","author":"Jochems","year":"2016","journal-title":"Oncotarget"},{"key":"B60","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.4049\/jimmunol.0803900","article-title":"NK cell responsiveness is tuned commensurate with the number of inhibitory receptors for self-MHC class I: the rheostat model","volume":"182","author":"Joncker","year":"2009","journal-title":"J. Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1084\/jem.20100570","article-title":"Mature natural killer cells reset their responsiveness when exposed to an altered MHC environment","volume":"207","author":"Joncker","year":"2010","journal-title":"J. Exp. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s44276-024-00064-8","article-title":"New light on chemotherapy toxicity and its prevention","volume":"2","author":"Juthani","year":"2024","journal-title":"BJC Rep."},{"key":"B63","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fimmu.2020.00167","article-title":"NK cell-based immune checkpoint inhibition","volume":"11","author":"Khan","year":"2020","journal-title":"Front. Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"16130","DOI":"10.18632\/oncotarget.7470","article-title":"IL-15 superagonist\/IL-15RalphaSushi-Fc fusion complex (IL-15SA\/IL-15RalphaSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas","volume":"7","author":"Kim","year":"2016","journal-title":"Oncotarget"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/s41590-026-02473-y","article-title":"Engineering NK and T cells with metabolite-sensing receptors to target solid tumors","volume":"27","author":"Kim","year":"2026","journal-title":"Nat. Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e002723","DOI":"10.1136\/jitc-2021-002723","article-title":"Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead","volume":"9","author":"Kirtane","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B67","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jcyt.2022.12.003","article-title":"The NK-92 cell line-30 years later: its impact on natural killer cell research and treatment of cancer","volume":"25","author":"Klingemann","year":"2023","journal-title":"Cytotherapy"},{"key":"B68","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fimmu.2016.00091","article-title":"Natural killer cells for immunotherapy - advantages of the NK-92 cell line over blood NK cells","volume":"7","author":"Klingemann","year":"2016","journal-title":"Front. Immunol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1080\/14712598.2020.1738379","article-title":"Rationale for IL-15 superagonists in cancer immunotherapy","volume":"20","author":"Knudson","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"B70","doi-asserted-by":"publisher","first-page":"636561","DOI":"10.3389\/fonc.2021.636561","article-title":"Value of adaptive trials and surrogate endpoints for clinical decision-making in rare cancers","volume":"11","author":"Krendyukov","year":"2021","journal-title":"Front. Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"102282","DOI":"10.1016\/j.xcrm.2025.102282","article-title":"Multiplexed iPSC platform for advanced NK cell immunotherapies","volume":"6","author":"Kumar","year":"2025","journal-title":"Cell Rep. Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"e70140","DOI":"10.1002\/ctm2.70140","article-title":"Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR","volume":"15","author":"Lam","year":"2025","journal-title":"Clin. Transl. Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/ni1581","article-title":"Up on the tightrope: natural killer cell activation and inhibition","volume":"9","author":"Lanier","year":"2008","journal-title":"Nat. Immunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e002128","DOI":"10.1136\/jitc-2020-002128","article-title":"Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells","volume":"9","author":"Lee","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B76","doi-asserted-by":"publisher","first-page":"101561","DOI":"10.1016\/j.cels.2026.101561","article-title":"NOT-gated chimeric antigen receptor circuits in T and NK cells","volume":"17","author":"Lee","year":"2026","journal-title":"Cell Syst."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e007725","DOI":"10.1136\/jitc-2023-007725","article-title":"First-in-human phase I\/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15Ralpha, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors","volume":"11","author":"Leidner","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"B78","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41423-020-0417-8","article-title":"Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics","volume":"17","author":"Li","year":"2020","journal-title":"Cell Mol. Immunol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-Positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"1603792","DOI":"10.3389\/fimmu.2025.1603792","article-title":"Adoptive cell therapy for cancer: combination strategies and biomarkers","volume":"16","author":"Liu","year":"2025","journal-title":"Front. Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","article-title":"Controlling natural killer cell responses: integration of signals for activation and inhibition","volume":"31","author":"Long","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1376622","DOI":"10.3389\/fonc.2024.1376622","article-title":"Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrence","volume":"14","author":"Lopez","year":"2024","journal-title":"Front. Oncol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3390\/cancers11060769","article-title":"Natural killer cells as allogeneic effectors in adoptive cancer immunotherapy","volume":"11","author":"Lupo","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B84","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1089\/152581601750288975","article-title":"Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92","volume":"10","author":"Maki","year":"2001","journal-title":"J. Hematother Stem Cell Res."},{"key":"B85","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41577-024-01022-8","article-title":"Engineering immune-evasive allogeneic cellular immunotherapies","volume":"24","author":"Martin","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.3389\/fimmu.2019.03038","article-title":"Influence of the tumor microenvironment on NK cell function in solid tumors","volume":"10","author":"Melaiu","year":"2019","journal-title":"Front. Immunol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/cancers12040952","article-title":"Natural killer cells: tumor surveillance and signaling","volume":"12","author":"Meza Guzman","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B88","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3389\/fimmu.2017.00304","article-title":"Type I interferons and natural killer cell regulation in cancer","volume":"8","author":"Muller","year":"2017","journal-title":"Front. Immunol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3390\/cancers11101534","article-title":"Natural killer cell therapy: a new treatment paradigm for solid tumors","volume":"11","author":"Oh","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B91","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","article-title":"Development of NK cell-based cancer immunotherapies through receptor engineering","volume":"21","author":"Page","year":"2024","journal-title":"Cell Mol. Immunol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-11-1347","article-title":"Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression","volume":"17","author":"Parkhurst","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","article-title":"CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors","volume":"21","author":"Peng","year":"2024","journal-title":"Cell Mol. Immunol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/cancers12030706","article-title":"You have got a fast CAR: chimeric antigen receptor NK cells in cancer therapy","volume":"12","author":"Pfefferle","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1286750","DOI":"10.3389\/fimmu.2023.1286750","article-title":"Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment","volume":"14","author":"Portillo","year":"2023","journal-title":"Front. Immunol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.smim.2006.03.003","article-title":"Missing self recognition and self tolerance of natural killer (NK) cells","volume":"18","author":"Raulet","year":"2006","journal-title":"Semin. Immunol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/annonc\/mdw413","article-title":"Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples","volume":"28","author":"Renfro","year":"2017","journal-title":"Ann. Oncol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"e54854","DOI":"10.7554\/eLife.54854","article-title":"Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells","volume":"9","author":"Robbins","year":"2020","journal-title":"Elife"},{"key":"B99","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"B101","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.coi.2005.01.007","article-title":"Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer","volume":"17","author":"Ruggeri","year":"2005","journal-title":"Curr. Opin. Immunol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1007\/s00262-012-1212-x","article-title":"Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor","volume":"61","author":"Sahm","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1038\/mt.2016.88","article-title":"Enhanced ADCC and NK cell activation of an anticarcinoma bispecific antibody by genetic insertion of a modified IL-15 cross-linker","volume":"24","author":"Schmohl","year":"2016","journal-title":"Mol. Ther."},{"key":"B104","volume-title":"Quilt-3.064: an open-label Phase I Study of PD-L1 t-haNK in Subjects with Locally Advanced or Metastatic Solid Cancers","author":"Seery","year":"2020"},{"key":"B105","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41571-020-00456-y","article-title":"Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells","volume":"18","author":"Shalabi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.chembiol.2017.08.002","article-title":"Emerging opportunities for target discovery in rare cancers","volume":"24","author":"Sharifnia","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40164-024-00561-z","article-title":"Natural killer cell-based cancer immunotherapy: from basics to clinical trials","volume":"13","author":"Shi","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"B109","volume-title":"QUILT 3.076 Phase 1 Study of Memory-like cytokine-enriched Natural Killer (M-CENK) Cells plus N-803 in Locally Advanced or Metastatic Solid Tumors","author":"Singh Nangia","year":"2025"},{"key":"B110","doi-asserted-by":"publisher","first-page":"e000246","DOI":"10.1136\/jitc-2019-000246","article-title":"Overcoming hypoxia-induced functional suppression of NK cells","volume":"8","author":"Solocinski","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B111","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","article-title":"NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy","volume":"65","author":"Suck","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"B112","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/nri3044","article-title":"NK cell development, homeostasis and function: parallels with CD8(+) T cells","volume":"11","author":"Sun","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/83416","article-title":"Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells","volume":"7","author":"Takeda","year":"2001","journal-title":"Nat. Med."},{"key":"B114","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"B115","doi-asserted-by":"publisher","first-page":"104553","DOI":"10.1016\/j.critrevonc.2024.104553","article-title":"Nature killer cell for solid tumors: current obstacles and prospective remedies in NK cell therapy and beyond","volume":"205","author":"Tao","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.3389\/fimmu.2019.02278","article-title":"NK cell metabolism and tumor microenvironment","volume":"10","author":"Terren","year":"2019","journal-title":"Front. Immunol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.stem.2024.06.009","article-title":"Disruption of TGF-beta signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells","volume":"31","author":"Thangaraj","year":"2024","journal-title":"Cell Stem Cell"},{"key":"B118","doi-asserted-by":"publisher","first-page":"6052","DOI":"10.1158\/1078-0432.CCR-19-0298","article-title":"Dose-ranging and cohort-expansion study of Monalizumab (IPH2201) in patients with advanced gynecologic malignancies: a trial of the Canadian Cancer Trials Group (CCTG): IND221","volume":"25","author":"Tinker","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","article-title":"Treatment of patients with advanced cancer with the natural killer cell line NK-92","volume":"15","author":"Tonn","year":"2013","journal-title":"Cytotherapy"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/ijc.34389","article-title":"The tumor microenvironment drives NK cell metabolic dysfunction leading to impaired antitumor activity","volume":"152","author":"Tumino","year":"2023","journal-title":"Int. J. Cancer"},{"key":"B121","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/blood.V100.4.1265.h81602001265_1265_1273","article-title":"Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction","volume":"100","author":"Uherek","year":"2002","journal-title":"Blood"},{"key":"B122","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1089\/cbr.2012.1329","article-title":"Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells","volume":"28","author":"Vallera","year":"2013","journal-title":"Cancer Biother Radiopharm."},{"key":"B123","doi-asserted-by":"publisher","first-page":"103013","DOI":"10.1016\/j.ctrv.2025.103013","article-title":"Overcoming the barriers to treatment of rare cancer patients in the era of precision oncology: a call to action","volume":"140","author":"van der Graaf","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"B124","doi-asserted-by":"publisher","first-page":"17675","DOI":"10.18632\/oncotarget.24832","article-title":"A phase 1 study of lirilumab (antibody against killer immunoglobulin-like receptor antibody KIR2D; IPH2102) in patients with solid tumors and hematologic malignancies","volume":"9","author":"Vey","year":"2018","journal-title":"Oncotarget"},{"key":"B125","doi-asserted-by":"publisher","first-page":"e186890","DOI":"10.1172\/jci.insight.186890","article-title":"Interim report on engineered NK cell trial in lung cancer refractory to immune checkpoint inhibitors","volume":"10","author":"Villalona-Calero","year":"2025","journal-title":"JCI Insight"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1002\/eji.201344272","article-title":"Effect of tumor cells and tumor microenvironment on NK-cell function","volume":"44","author":"Vitale","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","article-title":"Natural killer cell therapies","volume":"626","author":"Vivier","year":"2024","journal-title":"Nature"},{"key":"B128","doi-asserted-by":"publisher","first-page":"5932","DOI":"10.1038\/onc.2008.267","article-title":"NK cells and cancer immunosurveillance","volume":"27","author":"Waldhauer","year":"2008","journal-title":"Oncogene"},{"key":"B129","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3322\/caac.21689","article-title":"Radiation therapy-associated toxicity: etiology, management, and prevention","volume":"71","author":"Wang","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B130","first-page":"1161","article-title":"Temozolomide promotes immune escape of GBM cells via upregulating PD-L1","volume":"9","author":"Wang","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"B131","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41420-024-01815-9","article-title":"Breakthrough of solid tumor treatment: CAR-NK immunotherapy","volume":"10","author":"Wang","year":"2024","journal-title":"Cell Death Discov."},{"key":"B132","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","article-title":"Roles of natural killer cells in immunity to cancer, and applications to immunotherapy","volume":"23","author":"Wolf","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"5095","DOI":"10.4049\/jimmunol.175.8.5095","article-title":"Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity","volume":"175","author":"Woll","year":"2005","journal-title":"J. Immunol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1158\/2326-6066.CIR-15-0118","article-title":"Phase I study of random healthy donor-derived allogeneic natural killer cell therapy in patients with malignant lymphoma or advanced solid tumors","volume":"4","author":"Yang","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"B136","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.4049\/jimmunol.1701461","article-title":"Canonical TGF-beta signaling pathway represses human NK cell metabolism","volume":"200","author":"Zaiatz-Bittencourt","year":"2018","journal-title":"J. Immunol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41420-024-02077-1","article-title":"Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions","volume":"10","author":"Zhong","year":"2024","journal-title":"Cell Death Discov."},{"key":"B138","doi-asserted-by":"publisher","first-page":"840844","DOI":"10.3389\/fimmu.2022.840844","article-title":"NK cells equipped with a chimeric antigen receptor that overcomes inhibition by HLA class I for adoptive transfer of CAR-NK cells","volume":"13","author":"Zhuang","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2026.1955532\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:04:55Z","timestamp":1790172295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2026.1955532\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":138,"alternative-id":["10.3389\/fmolb.2026.1955532"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2026.1955532","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"article-number":"1955532"}}